Aura Biosciences, Inc.

AURA Nasdaq SEC CIK 1501796
Follow Aura Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$32.1M −22.7% vs same quarter last year
EPS, diluted −$0.29 +27.5% vs same quarter last year
Operating cash flow −$26.4M −31.3% vs same quarter last year
Operating income −$35.1M −25.6% vs same quarter last year
Net income by quarter
−$25.8M
−$27.5M
−$27M
−$26.1M
−$25.6M
−$33.7M
−$45.6M
−$32.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$106.2M
FY24−$86.9M
FY23−$76.4M
FY22−$58.8M
FY21−$35.3M
FY20−$22.2M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$85.2M
FY24−$81.1M
FY23−$64.6M
FY22−$55.7M
FY21−$34.5M
FY20−$25.1M
FY19-